IMMUNOCORE HLDGS ADS/1 (6YG) — Cash Flow Reinvestment Rate
IMMUNOCORE HLDGS ADS/1 (6YG) has a Cash Flow Reinvestment Rate of 0.05x as of June 2026, reinvesting €786.00K (capex €786.00K ) from operating cash flow of €15.93 Million. See 6YG FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
IMMUNOCORE HLDGS ADS/1 Cash Flow Reinvestment Rate (2023–2024)
Historical reinvestment intensity for IMMUNOCORE HLDGS ADS/1 across 2 annual periods. For the full cash flow conversion analysis, see IMMUNOCORE HLDGS ADS/1 cash conversion from operations.
Annual Cash Flow Reinvestment Rate for IMMUNOCORE HLDGS ADS/1 (2023–2024)
Year-by-year capital reinvestment analysis for IMMUNOCORE HLDGS ADS/1. See IMMUNOCORE HLDGS ADS/1 free cash flow to debt ratio to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (EUR) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2024 | 13.63x | €355.17 Million | €26.06 Million | €5.17 Million | ▲ +638.6% |
| 2023 | 1.85x | €5.42 Million | €2.94 Million | €5.42 Million | — |